Oral fosamprenavir for persistent heartburn
Part of Digestive system clinical trials.
This trial tests whether an oral medication called fosamprenavir can help with heartburn that isn't fully controlled by standard acid-reducing pills. If you have persistent heartburn despite treatment, this study may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 65 years old.
- You have had heartburn or reflux symptoms even while taking a daily standard-dose proton pump inhibitor (like omeprazole) for at least 8 weeks.
- You have had an endoscopy or pH test in the past 2 years that showed acid reflux or inflammation in the esophagus.
- You have had at least moderate heartburn on at least 2 days in the last week, with an average of mild or worse.
- You do not have other stomach conditions like functional dyspepsia or functional heartburn, or eosinophilic esophagitis (a type of allergy-related inflammation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new endoscopic procedure called anti-reflux mucosal ablation therapy to reduce acid reflux in people who still have symptoms despite taking acid-reducing medication. The goal is to see if this treatment helps improve heartburn and related symptoms.
This trial is testing a device called RefluxStop™ that is implanted during keyhole surgery to treat acid reflux (GERD). The study will check how safe and effective the device is for people with long-term GERD, and it aims to help reduce heartburn and other reflux symptoms.
This study looks at how following specific diet and behavior changes affects symptoms of acid reflux (heartburn/regurgitation) in everyday life. It may help you understand what lifestyle steps improve reflux and how symptoms change over time.
This Phase 2 study tests whether fosamprenavir can reduce inflammation and enzyme activity in the throat area for people with laryngopharyngeal reflux (LPR). If you still have LPR symptoms despite 3 months of twice-daily reflux medicine, this trial may offer another treatment approach.
This study tests a new medicine called vonoprazan to see if it can reduce episodes of heartburn in people who have GERD but no damage to their esophagus. It compares the medicine to a placebo (a pill with no active ingredient) over 24 weeks.
This study tests a new topical treatment for people with chronic heartburn and acid regurgitation who don't have erosions (damage) in their esophagus. The treatment is applied directly to the affected area and may help relieve symptoms without taking daily pills.
Hear when a new GERD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.